<?xml version="1.0" encoding="UTF-8"?>
<p>Although a potent, cost effective, and reliable MV-LAV is available, gaps in vaccination coverage have led to its resurgence in many areas of the world. In 2017, 110,000 deaths from measles were recorded [
 <xref rid="B99-vaccines-08-00036" ref-type="bibr">99</xref>], and the incidence of measles has continued to rise. The high communicability of MV necessitates a high level of global vaccination coverage, and the recent pattern of outbreaks due to vaccine hesitancy have the potential to undo decades of work invested into controlling this infectious disease. The Global Vaccine Action Plan aimed to eradicate measles (and rubella) in five WHO regions by 2020 [
 <xref rid="B100-vaccines-08-00036" ref-type="bibr">100</xref>], but MV-LAVs must be extensively utilized to accomplish any eradication in a timely manner. 
</p>
